A new review undertaken by academics fromThe University of New South Wales, published in the Journal of Neurology Neurosurgery Psychiatry, assessed six clinical trials (555 patients) and 30 observational studies (2,865 patients).
All the participants, whose average age was 16, had rare forms of epilepsy that had not responded to usual treatment.
Pooled analysis of the clinical trial data showed that CBD was more effective than a placebo at cutting seizure frequency by 50% or more, and at improving quality of life.
CBD was also more effective than placebo at eradicating seizures altogether, although this was still rare.
But the risk of side effects (dizziness and drowsiness), although small, was significant — 24% higher — while that of serious side effects was twice as high among those taking cannabidiol.
Data from 17 of the observational studies, meanwhile, showed that seizure frequency dropped by at least 50% in just under half of the patients and disappeared completely in